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Introduction: Regenerative medicine for the treatment of urinary incontinence has become a popular area of focus 
in the search for therapies for this disease. The paper focused on women’s quality of life assessment who were 
subjected to transplantation of MDSC (autologous muscle derived stem cells) to the urethral sphincter.
Methods: The procedure was conducted in 16 female patients who completed the observation stage. Assessment 
of quality of life before and after the treatment (two and four years post-operation) was conducted based on the 
validated I-QOL questionnaire (the Polish language version).
Results: The questionnaire study showed that autologous cell therapy significantly improves quality of life in female 
patients suffering from stress urinary incontinence (SUI). The total I-QOL score increased from 49 (SD ± 7.7) before 
therapy to 77 (SD ± 5.4) two years post-operation. Four years after the procedure, quality of life remained at a higher 
level than before therapy, although quality of life decreased by several points when compared with the results from 
the two-year follow-up -  63 (SD ± 7.2). Patients reported significantly less concern related to their ability to reach 
the toilet to avoid incontinence, improved sleep at night, a higher level of satisfaction with life, and more satisfaction 
with their sexual lives (p<0.05).
Conclusion: The MDSC injection procedure for SUI treatment has significant improved quality of life in the majority 
of our patients in 2 and 4 year follow-up.
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Streszczenie
Cel pracy: Medycyna regeneracyjna w leczeniu nietrzymania moczu stała się popularnym obszarem zainteresowania 
w poszukiwaniu metod leczenia tej choroby. Celem niniejszej pracy była ocena jakości życia u kobiet poddanych 
transplantacji autologicznych dojrzałych komórek pochodzących z mięśni (MDSC) do zwieracza cewki moczowej.
Materiał i metody: Badanie zostało przeprowadzone w grupie 16 pacjentek, które ukończyły etap obserwacji. Do 
oceny jakości życia przed i po leczeniu (w dwa i cztery lata po zabiegu) wykorzystano kwestionariusz I-QOL (polska 
wersja językowa).
Wyniki: Badania ankietowe wykazało, że terapia z wykorzystaniem autologicznych komórek mięśniowych 
w znacznym stopniu poprawia jakość życia pacjentek cierpiących z powodu wysiłkowego nietrzymania moczu 
(WNM). Całkowity wynik I-QOL wzrósł z 49 ± 7,7 (SD) przed leczeniem do 77 (SD ± 5,4) dwa lata po zabiegu. 
Cztery lata po zabiegu, jakość życia pozostał na poziomie wyższym niż przed leczeniem, chociaż zmniejszyła się 
o kilka punktów w porównaniu z wynikami z dwóch lat obserwacji - 63 (SD ± 7,2). Pacjentki zgłaszały znacznie 
mniej objawów związanych z ich możliwością dotarcia do toalety, wyższy poziom zadowolenia z życia i więcej 
satysfakcji z życia seksualnego (p <0,05).
Wnioski: Zastosowana procedura MDSC do leczenia wysiłkowego nietrzymania moczu skutecznie poprawiła 
jakość życia u większości analizowanych pacjentek po 2 i 4 latach od zbiegu.
Słowa kluczowe: jakość życia wysiłkowe nietrzymanie moczu terapia nietrzymania 
moczu mięśniowe komórki macierzyste
Introduction
Statistics show that UI (urinary incontinence) is a maj or 
health, social and economic problem [1]. The International 
Continence Society (ICS) suggested that approximately 8-58% 
of  adult women suffer from UI at some point in their lives [2, 
3]. The gold standard in the treatment of  SUI (stress urinary 
incontinence) in woman are the suburethral slings (retropubic 
or transobturator approach) with up to 90% cure rate for a long 
time. Despite the high success rates, 10-20% of  women stay 
incontinent. Possible complications of  sling are e.g. tape erosion, 
obstructive voiding and dyspareunia. Patients with structurally 
damaged sphincter may benefit from an alternative therapy called 
cell-based therapy[4]. The crucial part of  this method is the 
chosen cell’s type or combination of  them as well as, the inj ection 
technique for proper material placing [5, 6]. Stem cells treatment 
can differentiate into smooth muscle cells and regenerate the 
damaged tissue (urethral sphincter). It might be an additional 
paracrine mechanism o f  action, by secreting factors that modulate 
local responses [7]. Regardless of  the mechanism of  action, every 
procedure and especially a new one, requires verification through 
personal subj ected both in terms of  side effects and long-term 
effects [8].
To assess the effects of  UI on patient quality of  life in an 
obj ective manner validated versions of  questionnaires are used 
like e.g. I-QOL (Incontinence Quality o f  Life) which is available 
in the Polish language [9].
Materials and Methods
The aim of  the study was to evaluate patients with SUI 
(stress urinary incontinence) who were involved into the pilot 
study previously conducted from 2009 to 2011 in the Clinic 
of  Gynecology and Oncology, JU CM, for MDSC (autologous 
muscle derived stem cells) urethral sphincter inj ection. The 
women participating in the study completed an identical
questionnaire to assess their quality of  life (I-QOL) prior and two 
and four years after the procedure with the following results.
The inj ection procedure tissue material for the study was 
acquired from deltoid muscle biopsies. Cell culture of  the 
biopsied tissue produced suspended cellular matter, which was 
applied in the urethral sphincter region circumferential (at 9, 12 
and 3 o ’clock position) in a group of  16 women. Preoperatively 
collected general data, medical treatment already used for SUI 
and past medical history. This trial has gained positive approval 
from the Jagiellonian University Bioethical Committee. Two 
years after the procedure, positive results from the therapy were 
self-reported by 75% of  the women as we previously reported 
[10, 11].
Questionnaire tools fo r  the assessment o f  quality o f  life
The I-QOL questionnaire was designed to be used in clinical 
trials as a disease-specific instrument to measure the impact of  
UI on the quality of  life in men and women experiencing urge, 
stress, and mixed UI [9]. The questionnaire recommendation has 
been given a Grade A status, indicating its validity, reliability and 
responsiveness as established with rigor in several data sets at 
the Fourth International Incontinence Consultation in2010 [12].
Statistical methods
The R Package was used for our statistical analysis [13]. 
The data were analyzed based on Fisher’s exact test (some cells 
in the contingency tables had an expected frequency of  five or 
less). Assessment o f  the questionnaire data was based on the 
I-QOL score. The subscale scores were computed by adding 
each response, subtracting the lowest possible score and dividing 
that sum by the possible raw score range. The scores were then 
transformed to present within a range from 0 (maximum problem) 
to 100 (no problem at all).
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Table I. Mean I-QOL scores and standard deviations across all studies; y0 -  before the treatment; y2 -  two years after the treatment; y4 -  four years after the treatment
Period of 
tim e
I-Q O L  
Total Score
A vo idance &  
Lim iting  
B ehaviors Score
P sychosocial 
Im pacts Score
Social
E m b arrassm ent
S core
M ean (SD) M ean (SD) M ean (SD) M ean (SD)
y4 63 ±7.2 67 ±7.01 64 ±5.5 55 ±4.7
У2 77 ±5.4 78 ±4.7 78 ±4.9 73 ±6.1
y0 49 ±7.7 47  ±8 .15 53 ±7.5 46 ±5.6
Table II. Summary of questionnaire responses (I-QOL) related to avoidance and limiting behavior to assess the quality of life of patients before (y0) and after cell 
transplantation (y2 -2  years after treatment, y4 -4  years after treatment).
I-Q O L questions
I-Q O L score F isher test; p-value
y0 y2 y4 y0-y2 y0 -y4 y2 -y4
A
vo
id
an
ce
 
an
d 
Li
m
iti
ng
 
B
eh
av
io
r 
(A
LB
)
1 1 w orry  about not being ab le to ge t to  the to ile t on 
time. 42 75 72 0.008863 0.04825
0.8417
2 1 w orry  about coughing o r sneezing because o f my urinary p rob lem s o r incontinence. 45 83 66 0.0001446 0.05164 0.2161
3
1 have to be carefu l stand ing up a fte r I’ve  been 
sitting down because o f m y urinary prob lem s or 
incontinence.
58 83 77 0.2967 0.6743 0.9155
4 I w orry  about w here  to ile ts  are in new  places. 38 78 59 0.0007211 0.1179 0.2569
10 It’s im portan t fo r m e to m ake frequen t trips to the toilet. 38 73 58 0.004844 0.1753 0.5563
11 B ecause o f my urinary p rob lem s o r incontinence, it’s im portan t to plan eve ry  detail in advance. 59 84 70 0.04821 0.08051 0.5579
13 I have a hard tim e getting a good n igh t o f sleep because o f m y urinary prob lem s o r incontinence. 50 78 73 0.04571 0.01515 1
20 I have to w atch w ha t o r how  m uch I d rin k  because of m y urinary p rob lem s o r incontinence. 48 72 61 0.02683 0.4244 0.4748
Table I I I .  Summary of questionnaire responses (I-QOL) for the group of questions related to psychosocial impacts to assess the quality of life of female patients before (y0) 
and after cell transplantation (y2 - after 2 years, y4 - after 4 years).
I-Q O L questions
I-Q O L score F isher test; p-value
y0 y2 y4 y0-y2 y0 -y4 y2 -y4
P
sy
ch
os
oc
ia
l 
Im
pa
ct
s 
(P
S
)
5 I fee l depressed because o f m y urinary prob lem s o r incontinence. 67 83 64 0.1186 0.5132 0.6177
6
Because o f my urinary p rob lem s o r incontinence,
I d o n ’t fee l free  to  leave m y hom e fo r long periods o f 
time.
59 86 72 0.03931 0.05461 0.5857
7 I fee l frustra ted because m y urinary prob lem s o r incontinence prevent m e from  doing w ha t I want. 53 77 64 0.05104 0.06639 0.5857
9 My urinary p rob lem s o r incontinence are a lw ays on my m ind. 44 75 59 0.005987 0.06639 0.5647
15 My urinary p rob lem s o r incontinence m ake me fee l like I’m not a healthy person. 47 72 61 0.2503 0.587 0.8921
16 M y urinary prob lem s o r incontinence m ake me fee l help less. 48 73 59 0.2503 0.07039 0.7938
17 I ge t less en joym en t ou t o f life because o f m y urinary prob lem s o r incontinence. 47 75 64 0.01035 0.05359 0.7848
21 M y urinary prob lem s o r incontinence lim it my cho ice o f cloth ing. 56 80 58 0.01371 0.4011 0.4202
22 I w orry  about having sex because o f my urinary prob lem s o r incontinence. 59 83 73 0.007611 0.01848 0.7888
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Figure 1. Incidence of patients responding to the questions related to avoidance and limiting behavior. The charts refer to data for which the result of the statistical study was 
significant (p<0.05). y0 -  black (before treatment); y2 -  light gray (2 years after treatment); y4 -  gray (4 years after treatment).
Results
I-QOL questionnaire interviews were related to avoidance 
and limiting behavior (ALB), psychosocial impact (PS) and social 
embarrassment (SE). Comparison of  the answers of  the patients 
showed that the comprehensive I-QOL score (determining the 
level of  quality of  life on a scale of  0-100) was significantly 
improved. Two years after the procedure, I-QOL increased 
from 49 to 77. The quality of  life decreased by four years post­
procedure to 63, although the average quality of  life score at this 
time point remained higher than pre-procedure (Table I).
The greatest increase among all quality of life measures was 
observed for avoidance and limiting behavior (ALB) at two years 
(y2) after the treatment. ALB scores were 31 points higher at y2 
than before the treatment (y0). ALB scores showed the greatest 
improvement at the four-year (y4) time point as well, as ALB 
scores remained higher by 20 points when compared with pre­
treatment (y0) values.
Social embarrassment (SE) scores showed the lowest degree 
of  improvement over the course of  the study. The average SE 
score two years after the procedure was 73, which was higher 
than the average SE score before the treatment (y0) by 27 points. 
However, the decrease in the average SE score between y2 and 
y4 was 18 points, which represents the strongest decrease of  all 
quality oflife subcategories (ALB, PS and SE). These results may 
suggest that failures related to treating SUI are most apparent in 
deterioration in the quality of life related to SE.
Avoidance and Limiting Behavior (ALB)
Patient responses after treatment indicated a clear decrease 
in the fear of  not reaching the toilet in time and in the fear that 
sneezing or coughing may cause incontinence. A decrease in 
these fears was recorded 2 and 4 years after the treatment relative 
to patient responses before the procedure (questions 1 and 2 in 
Table II). Anxiety related to constantly thinking about the nearest 
bathroom also showed a significant decrease (question 4, Table
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Figure 2. Incidence of female patients responding to questions related to psychosocial impacts. The charts refer to data for which the result of the statistical study was significant 
(p<0.05). y0 -  black (before treatment); y2 -  light gray (2 years after treatment); y4 -  gray (4 years after treatment).
II). Despite the small sample size, a positive trend was obvious 
(increased quality of life in patients) after the procedure (Figure 
1). However, we note that the I-QOL quality o f life coefficient 
decreased between two years (y2) and four years (y4) after the 
procedure.
No correlation was observed between the effects o f the 
therapeutic procedure and either the required effort to avoid 
urinating while standing up or patient awareness of what they 
drink and in what quantity (p>0.05; Table II).
Psychosocial Impacts (PS)
In women who experience UI, in addition to the physiological 
inconvenience, some psychological symptoms were reported that 
affected the physical and mental condition of the patients, their 
self-assessment and their ability to function in life. Many female 
UI patients experience depression and frustration. Constantly 
thinking about UI causes continuous awareness and pressure, 
which can result in fear of sexual activity. Patients often indicate 
their helplessness and a general lack ofjoy in life due to SUI.
The effects o f MDC therapy indicate that reduction 
or elimination of the physiological problems related to UI 
significantly increases self-assessment in female patients in many
areas of  psychology (Table III). Interestingly, the positive effects 
decreased slightly over time. Four years after the procedure, 
fewer patients stated positive change related to UI (Table III, 
Figure 2).
In most cases, patients with persistent thoughts about UI 
stated that after the cell therapy, they thought less constantly 
about their condition (Figure 2). Similar results were observed 
with respect to questions about the general satisfaction with 
life of  the patients. Patients mostly reported an increase in their 
ability to function and a decrease in frustration. In addition, the 
sexual lives of  the patients improved (Figure 2).
Patient responses to some questions did not change 
statistically significantly regardless o f  the time of  the 
questionnaire (before therapy, two years after and four years 
after). For the question about feeling depressed, the patients 
depression due to their illness. Similar results were obtained 
with respect to the question about feeling helpless. Interestingly, 
each response group (corresponding to EXTREMELY, QUITE 
A BIT, MODERATELY, A LITTLE and NOT AT ALL) featured 
similar proportions of  patients, even though the largest group of  
responses was observed in patients who did not feel depressed or 
helpless due to their ailment (Table III).
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Table IV. Summary of questionnaire responses (I-QOL) corresponding to social embarrassment questions to assess the quality of life of female patients before (y0) and after 
cell transplantation (y2 - 2 years after treatment, y4 - 4 years after treatment).
I-Q O L questions
I-Q O L score F isher test; p-value
y0 У2 y4 y0-y2 y0 -y4 y2 -y4
S
oc
ia
l
E
m
ba
rr
as
sm
en
t
(S
E
)
8 1 w orry  about o thers sm elling urine on me. 48 78 58 0.07711 0.5374 0.4114
12 1 w orry  about my urinary p rob lem s o r incon tinence getting w orse 
as I g row  older.
41 63 47 0.3527 0.2469 0.5608
14
1 w orry  about being em barrassed o r hum ilia ted because o f my 
urinary prob lem s o r incontinence
55 78 58 0.3735 0.5988 0.5413
18 1 w orry  about w etting myself. 47 72 58 0.03846 0.08956 0.3501
19 I fee l like I have no contro l o ve r m y bladder. 42 72 56 0.02707 0.05051 0.2773
Figure 3. Incidence of female patients responding to the questions related to social embarrassment (SE). The charts refer to data for which the results of the statistical study were 
significant at two years after the treatment (p<0.05). y0 -  black (before treatment); y2 -  light gray (2 years after treatment); y4 -  gray (4 years after treatment).
Social Embarrassment (SE)
This study showed that stress involved in UI is to some extent 
continuous (despite positive therapeutic effects). For example, 
patients remained concerned that their UI problem would recur 
after some time (Table IV).
The patients expressed the fear that others may smell the 
odor of  urine as well as a fear of  their incontinence and a lack of  
control over their bladder (Figure 3).
Discussion
Treatment of  incontinence is different from other fields 
of  health care in that health related quality of  life is seen as 
the central goal, not as a secondary outcome. For obj ective 
evaluation of  quality of  life assessment, different validated 
questionnaires are used. They should be translated into the 
language of  the country like e.g. I-QOL [9]. Assessment of  the 
clinical condition and the questionnaire results prior and 2 and 4 
years after the MDC treatment was administered in women with 
stress UI indicates that the therapeutic result is durable in the
1 8 8  ©  P o l s k i e  T o w a r z y s t w o  G i n e k o l o g i c z n e  Nr 3 /2 0 1 6
G in e k o l P o l. 2 0 1 6 ,  8 7 , 1 8 3 -1 8 9 DOI: 10.17772/gp/61330 P R A C E  O R Y G I N A L N E
g i n e k o l o g i a
Klaudia Stangel-Wojcikiewicz et al. Quality o f life assessment in female patients 2  and 4 years after muscle-derived cell transplants for stress urinary incontinence treatment.
maj ority of  the included patients. Importantly, improvements in 
patient function were observed in areas such as social life, family 
life, j ob/work, intimate relationships, daily activities, household 
activities, recreation and travel, mental health, physical health 
and anxiety/depression. The psychological condition of  the 
patients significantly improved. We suspect that improvement in 
patient comfort and an increase in the time needed to reach a toilet 
without experiencing incontinence may be factors in determining 
social behavior o f  the patients. With these improvements, the 
patients reported feeling more self-confident. None of  the women 
subj ected to the treatment reported negative feedback with 
respect to the therapy itself, even if  total control over urination 
was not gained. Moreover, in response to the question about 
whether the patients would participate in another round of  the 
therapy, they declared a willingness to continue their treatment. 
However, it is difficult to compare results across studies, Carr 
et al. demonstrated autologous muscle derived cells (AMDC) 
dose range inj ection safety with the quality of  life assessment. 
Mean IIQ-7 scores for low and high dose groups did not differ 
significantly at baseline or 18 months. Mean UDI-6 scores for 
patients in low and high dose groups differed significantly from 
baseline to 18 months [14]. Blaganj e et al. inj ected autologous 
muscle-derived stem cells in 38 women with SUI. Initially 
the women were treated with electrical stimulation alone for 6 
weeks. Then the stem cells were inj ected, and another 6 weeks 
of  electrical stimulation were given. At the end of  this 6-week 
period, 5 women were cured and 29 improved. Unfortunately, 
there was no control group [15].
So far, no randomized controlled data are available, nor are 
there any comparison assessment suburethral sling procedures 
with MDSC treatment. Dosage of  cells inj ected, number of  
inj ection and the method of  delivery are other factors that need to 
be addressed in a future study. Nonetheless, all studies published 
to date report low rates of  operative morbidity for intrasphincter 
inj ection of  autologous muscle cells.
Conclusion
The MDSC inj ection procedure for SUI treatment has 
significant improved quality o f life in the maj ority of  our patients 
in 2 and 4 year follow-up.
Ethical approval: All procedures performed in the studies 
involving human participants were in accordance with the ethical 
standards o f the institution and/or national research committee 
and with the 1964 Helsinki declaration and its amendments or 
comparable ethical standards.
Informed consent: Informed consent was obtained.
Oświadczenie autorów:
1. Klaudia Stangel-Wójcikiewicz -  autor koncepcji i założeń pracy, 
przygotowanie manuskryptu i piśmiennictwa -  autor zgłaszający i 
odpowiedzialny za manuskrypt.
2. Monika Piwowar -  zebranie materiału, analiza statystyczna wyników, 
przygotowanie manuskryptu.
3. Robert Jach -  autor założeń pracy, analizy i interpretacji wyników, 
przygotowanie, korekta i akceptacja ostatecznego kształtu manuskryptu.
4. Marci n Majka -  współautor tekstu pracy i protokołu, korekta i aktualizacja 
literatury.
5. Antoni Basta -  ostateczna weryfikacja i akceptacja manuskryptu.
Źródło finansowania:
Praca nie była finansowana przez żadną instytucję naukowo-badawczą, 
stowarzyszenie ani inny podmiot, autorzy nie otrzymali żadnego grantu.
Konflikt interesów:
Autorzy nie zgłaszają konfliktu interesów oraz nie otrzymali żadnego 
wynagrodzenia związanego z powstawaniem pracy.
References
1. Buckley BS, Lapitan MC. Prevalence of urinary incontinence in men, women, and children- 
current evidence: findings of the Fourth International Consultation on Incontinence. Urology. 
2010, 76 (2), 265-270.
2. Ebbesen MH, Hunskaar S, Rortveit G, [et al.]. Prevalence, incidence and remission of urinary 
incontinence in women: longitudinal data from the Norwegian HUNT study (EPINCONT). BMC 
Urol. 2013, 13, 27.
3. Tang DH, Colayco D, Piercy J, [et al.]. Impact of urinary incontinence on health-related quality 
of life, daily activities, and healthcare resource utilization in patients with neurogenic detrusor 
overactivity. BMC Neurol. 2014, 14, 74.
4. Carr LK, Robert M, Kultgen PL, [et al.]. Autologous muscle derived cell therapy for stress urinary 
incontinence: a prospective, dose ranging study. J  Urol. 2013, 189 (2), 595-601.
5. Hart ML, Izeta A, Herrera-Imbroda B. [et al.]. Cell therapy for stress urinary incontinence. Tissue 
Eng Part B Rev. 2015, 21,: 365-376.
6. Stoltz J-F, de Isla N, Li Y, [et al.]. Stem cells and regenerative medicine: myth or reality of the 
21th century. Stem Cells Int. 2015, ID: 734731.
7. Hakim L, De Ridder D, Van der Aa F. Slings for urinary incontinence and the application of cell- 
based therapy. AdvDrug DelivRev. 2015, 82-83, 22-30.
8. Fabian G, Barcz E, Zwierzchowska A, [et al.]. Complications of sub-urethral sling procedures. 
G inekolPol 2014, 85 (7), 536-540.
9. Patrick DL, Martin ML, Bushnell DM, [et al.]. Quality of life of women with urinary incontinence: 
further development of the incontinence quality of life instrument (I-QOL). Urology 1999, 53 (1), 
71-76.
10. Stangel-Wojcikiewicz K, Jarocha D, Piwowar M, [et al.]. Autologous Muscle-Derived Cells for the 
Treatment of Female Stress Urinary Incontinence: A 2-Year Follow-Up of a Polish Investigation. 
Neurourol Urodyn. 2014, 33 (3), 324-330.
11. Stangel-Wojcikiewicz K. Medycyna regeneracyjna w  leczeniu nietrzymania moczu. 
Wydawnictwo Uniwersytetu Jagiellońskiego, Kraków, 2014.
12. Abrams P, Andersson KE, Birder L, [et al.]. Fourth International Consultation on Incontinence 
Recommendations of the International Scientific Committee: Evaluation and treatment of urinary 
incontinence, pelvic organ prolapse, and fecal incontinence. Neurourol Urodyn. 2010, 29 (1), 
213-240.
13. R Core Team. A Language and Environment for Statistical Computing. Vienna, Austria. 2011. 
Retrieved from http://www.r-project.org/
14. Carr L, Magali R, Kultgen PL, [et al.]. Autologous Muscle Derived Cell Therapy for Stress Urinary 
Incontinence: A Prospective, Dose Ranging Study. J  Urol 2013,189, 595-601.
15. Blaganje M, Lukanović A. Intrasphincteric autologous myoblast injections with electrical 
stimulation for stress urinary incontinence. Int J  Gynaecol Obstet. 2012, 117 (2), 164-167.
Nr 3 / 2 0 1 6  ©  P o l s k i e  T o w a r z y s t w o  G i n e k o l o g i c z n e  1 8 9
